Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1010)	6/11/1999 2:09:00 PM
From: SDR-SI	Respond to of 1686

To all: Just a quick note from today's Annual Meeting. As usual, it was a very upbeat and forward looking event and a clear demonstration of the company's commitment to its goal of being the largest and most profitable of the biotechnology-based pharmaceutical companies. Presentations were made on the outlooks for further development of Avonex, and for movement toward development and marketing of Amevive, Antova and Adenosine. Highlights included the reintroduction of key executives and the fact that all of the recent changes in senior management have come from promotion from within. Following is a key chart displayed by Jim Vincent which is somewhat indicative of the direction in which the company is heading and which is indicative of the reasons for confidence in its ability to meet its ambitious goals: COMPOSITE OF ITEM 8 COMPETITORS BIOGEN ---------------- ------------- ----------- CGS 24% 13% SGA 31% 21% R&D 19% 32% Net Profit 18% 25% Figures are percentages of sales. "8 Competitors" list includes Amgen, Merck, Pfizer, Pharmacia, etc. Key comparisons pointed out were the "inversion" of the SGA and R&D percentages in comparing the others to Biogen and the effect of the company's low overall cost of product compared to the others. The net result of 25% vs. 18% bottom line, while spending well more than 1 1/2 times as much on R&D percentage-wise, indicates the direction in which one would expect the company to be going. Steve